Viking Therapeutics (VKTX): Assessing Valuation Amid Rising Investor Confidence in Obesity Drug Pipeline and Upcoming Earnings Report
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 19 2025
0mins
Source: Yahoo Finance
Viking Therapeutics Overview: The company is gaining attention due to its advancing clinical pipeline, particularly the VK2735 obesity drug in phase 3 trials, and a recent 45% share price increase despite a challenging year.
Valuation Insights: Viking Therapeutics has a price-to-book (P/B) ratio of 4.7x, which is lower than its peers but higher than the industry average, indicating potential undervaluation amidst optimism about its drug pipeline and caution regarding its unproven profitability.
VKTX
$37.18+Infinity%1D
Analyst Views on VKTX
Wall Street analysts forecast VKTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VKTX is 97.27 USD with a low forecast of 70.00 USD and a high forecast of 125.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
13 Analyst Rating
13 Buy
0 Hold
0 Sell
Strong Buy
Current: 37.350
Low
70.00
Averages
97.27
High
125.00
Current: 37.350
Low
70.00
Averages
97.27
High
125.00
About VKTX
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on the development of therapies for the treatment of metabolic and endocrine disorders. Its clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptors for the potential treatment of various metabolic disorders. It is evaluating an oral formulation of VK2735 in a Phase II trial. It is also developing VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders. Its newest program is evaluating a series of internally developed dual amylin and calcitonin receptor agonists for the treatment of obesity and other metabolic disorders. In the rare disease space, it is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
